Major advances in the treatment of hepatitis C
The provision of funded treatment for hepatitis C in primary health is a fundamental change in the treatment of hepatitis C
Pātiki and Waharua Kōpito patterns
Pātiki and Waharua Kōpito patterns
Are you at risk?
Check whether you’re at risk of hepatitis C and choose where to get tested
PHARMAC-funded direct acting antivirals drugs and their treatment numbers since 2019 as follows:
| Harvoni | 222 |
| Viekira Pak | 3186 |
| Maviret | 5180 |
| Total | 8588 |
Since February 2019, around 5,000 New Zealanders with hepatitis C have been treated with Maviret, a new direct-acting antiviral treatment funded by PHARMAC.
Maviret is simple to administer, has fewer side effects than previous treatments, and can potentially cure 98 percent of people with chronic hepatitis C.
Refer to the PHARMAC website for further details about the funded treatment options and for information for people with hepatitis C, for prescribers and for pharmacists: